Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Journal of Endotoxin Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Opal, S.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Opal, S.M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Lessons learned from clinical trials of sepsis

S.M. Opal

Brown University School of Medicine, Providence, Division of Infectious Diseases, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, USA

The development of novel therapeutic agents with demonstrable clinical efficacy in septic patients has proven to be an elusive goal. Despite a biologically plausible therapeutic rationale, antisepsis drugs have not performed consistently or convincingly in recent clinical trials. A great deal of information has been learned recently about the basic mechanisms and molecular pathophysiology of sepsis. Nonetheless, the optimal patient population, the clinical and laboratory indicators to predict outcome and susceptibility to treatment, and the most appropriate clinical endpoints have yet to be clearly defined. Refinements in clinical trial design may be as important as basic discoveries in molecular biology in the future development of new therapeutic agents in septic shock.

Journal of Endotoxin Research, Vol. 2, No. 3, 221-226 (1995)
DOI: 10.1177/096805199500200313
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?